Cargando…

SARS-CoV-2, COVID-19 and Parkinson’s Disease—Many Issues Need to Be Clarified—A Critical Review

Neurological manifestations during the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic are of interest, regarding acute treatment and the so-called post-COVID-19 syndrome. Parkinson’s disease (PD) is one of the most common neurodegenerative movement disorders worldwide. Hence,...

Descripción completa

Detalles Bibliográficos
Autores principales:	Goerttler, Tsepo, Kwon, Eun-Hae, Fleischer, Michael, Stettner, Mark, Tönges, Lars, Klebe, Stephan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9028450/ https://www.ncbi.nlm.nih.gov/pubmed/35447986 http://dx.doi.org/10.3390/brainsci12040456

Ejemplares similares

Monogenetic Forms of Parkinson’s Disease – Bridging the Gap Between Genetics and Biomarkers
por: Tönges, Lars, et al.
Publicado: (2022)

SARS-CoV-2, COVID-19 and Neurodegeneration
por: Tönges, Lars, et al.
Publicado: (2022)

Adult-Onset Alexander Disease: New Causal Sequence Variant in the GFAP Gene
por: Goerttler, Tsepo, et al.
Publicado: (2022)

Blood-based biomarker in Parkinson’s disease: potential for future applications in clinical research and practice
por: Tönges, Lars, et al.
Publicado: (2022)

Update on CSF Biomarkers in Parkinson’s Disease
por: Kwon, Eun Hae, et al.
Publicado: (2022)

Clinical Profiles and Mortality of COVID‐19 Inpatients with Parkinson's Disease in Germany
por: Scherbaum, Raphael, et al.
Publicado: (2021)

Inner Peace needs of male psychiatric patients in post-war Croatia are associated with their needs to clarify open issues in their life and their needs for forgiveness
por: Glavas, Andrijana, et al.
Publicado: (2023)

Strategic Planning: Establishing Need and Clarifying Motivation
por: Wilson, Samuel H., et al.
Publicado: (2005)

COVID-19 outcomes in hospitalized Parkinson’s disease patients in two pandemic waves in 2020: a nationwide cross-sectional study from Germany
por: Scherbaum, Raphael, et al.
Publicado: (2022)

Short-chain fatty acids in the context of Parkinson’s disease
por: Metzdorf, Judith, et al.
Publicado: (2021)

Screening for Aortic Aneurysm: Further Evidence is Required to Clarify the Issue
por: Hozawa, Atsushi
Publicado: (2021)

Anti-GFAP-antibody positive postinfectious acute cerebellar ataxia and myoclonus after COVID-19: a case report
por: Asan, Livia, et al.
Publicado: (2021)

Resource Utilization of Patients with Parkinson’s Disease in the Late Stages of the Disease in Germany: Data from the CLaSP Study
por: Kruse, Christopher, et al.
Publicado: (2021)

Emergencies and critical issues in Parkinson’s disease
por: Simonet, Cristina, et al.
Publicado: (2020)

Clarifying the role of three-dimensional transvaginal sonography in reproductive medicine: an evidenced-based appraisal
por: Raine-Fenning, Nick, et al.
Publicado: (2005)

Mutations in 12 known dominant disease-causing genes clarify many congenital anomalies of the kidney and urinary tract
por: Hwang, Daw-Yang, et al.
Publicado: (2014)

Unmet need for critical care on the wards - how many critically ill patients are really out there?
por: Newell, CP, et al.
Publicado: (2015)

Adenosin A (2A) Rezeptorantagonisten als Therapieoption beim idiopathischen Parkinson-Syndrom?
por: Jost, Wolfgang H., et al.
Publicado: (2022)

An Issue Waiting to be Clarified: Effects of the QT Prolonging Drugs on Tp-e Interval
por: Yiginer, Omer, et al.
Publicado: (2015)

Clarifying Water
Publicado: (1867)

Clarifying Water
Publicado: (1879)

Need for universal critical care guidelines template: Difficult to choose from many!
por: Ahmed, Syed M, et al.
Publicado: (2020)

Many More Dentists Needed
por: Lee, Alfred P.
Publicado: (1913)

A Myth Still Needs to be Clarified: A Case Report of the Frank's Sign
por: Lin, Aung Naing, et al.
Publicado: (2018)

Personal genome testing: Test characteristics to clarify the discourse on ethical, legal and societal issues
por: Bunnik, Eline M, et al.
Publicado: (2011)

Letter to the editor: risk comorbidities of COVID-19 in Parkinson’s disease patients in Germany
por: Richter, Daniel, et al.
Publicado: (2020)

How many markers are needed to robustly determine a cell's type?
por: Fischer, Stephan, et al.
Publicado: (2021)

How many markers are needed to robustly determine a cell’s type?
por: Fischer, Stephan, et al.
Publicado: (2022)

Clarifying the Mechanisms of Antidepressants
por: Tucker, Don M.
Publicado: (2015)

Clarifying the origin of Houzao
por: Zhao, Zhongzhen, et al.
Publicado: (2018)

Modulation of Microglial Activity by Rho-Kinase (ROCK) Inhibition as Therapeutic Strategy in Parkinson’s Disease and Amyotrophic Lateral Sclerosis
por: Roser, Anna-Elisa, et al.
Publicado: (2017)

Chagas Disease: Still Many Unsolved Issues
por: Álvarez, José M., et al.
Publicado: (2014)

Hospital Admissions for Neurodegenerative Diseases during the First Wave of the COVID-19 Pandemic: A Nationwide Cross-Sectional Study from Germany
por: Scherbaum, Raphael, et al.
Publicado: (2021)

How Many People Need Palliative Care and How Many Miss Out?
por: Davis, Esther, et al.
Publicado: (2020)

Building a Parkinson-Network–Experiences from Germany
por: van Munster, Marlena, et al.
Publicado: (2020)

Emerging Immunotherapies for Parkinson Disease
por: Zella, Samis M. A., et al.
Publicado: (2018)

Parkinson’s Disease: A Tale of Many Players
por: Pauwels, Ernest K. J., et al.
Publicado: (2023)

Many Faces of Parkinson’s Disease: Non-Motor Symptoms of Parkinson’s Disease
por: Lee, Hye Mi, et al.
Publicado: (2015)

Propionic Acid and Fasudil as Treatment against Rotenone Toxicity in an In Vitro Model of Parkinson’s Disease
por: Ostendorf, Friederike, et al.
Publicado: (2020)

Use of Condoms: Clarifying the Message
por: Majra, JP
Publicado: (2010)

Cannot write session to /tmp/vufind_sessions/sess_g89ugv7iiv6r1d36arkog1sart